by Ellie Lampton | Jan 13, 2026
A breakthrough prospective research model that unites proprietary data, real-world clinical evidence, expert determination, and integrated storage in one solution BELLEVUE, Wash.—January 13, 2026—Truveta, the health system-led data and analytics company, today...
by Ellie Lampton | Jan 2, 2026
BELLEVUE, Wash.—January 2, 2026—Truveta today announced the publication of new peer-reviewed research in JAMA Network Open that provides one of the most comprehensive and timely analyses to date on childhood measles, mumps, and rubella (MMR) vaccination trends in the...
by Ellie Lampton | Nov 14, 2025
Truveta’s analysis of early measles, mumps, and rubella (MMR) vaccinations among Texas infants published today in JAMA Network Open. The study reveals a sharp increase in early MMR vaccinations among infants in Texas during the state’s 2025 measles outbreak, aligning...
by Ellie Lampton | Oct 29, 2025
Truveta is proud to announce the publication of its latest peer-reviewed research in Radiology Advances: “XComposition: Multimodal Deep Learning Model to Measure Body Composition Using Chest Radiographs and Clinical Data.” This groundbreaking study demonstrates the...
by Ellie Lampton | Sep 23, 2025
Unique device identifier data linked with ADT and chargemaster data give medical device manufacturers unmatched visibility into device use, safety, and outcomes—accelerating regulatory submissions, discovering safety signals faster, and speeding innovation that shapes...
